iiinova — where your digital self keeps evolving

Rémy Duléry @remydulery.bsky.social · 24/04/2025

Happy to participate to the 15th Forum for Cellular and Humoral Immunotherapy today at 4pm CET. I will discuss the risks of secondary malignancy after #CARTcell therapy. Feel free to register👉 us06web.zoom.us/webinar/regi...

010

Rémy Duléry @remydulery.bsky.social · 03/04/2025

Honored to present our latest #RomeeLab research on engineering IL-12-secreting CAR NK cells to target high-risk AML—demonstrating feasibility, safety, and efficacy. What a pleasure to be at #EBMT25 in Florence! 🇮🇹🌞

010

Rémy Duléry @remydulery.bsky.social · 01/04/2025

Delighted to see a packed and engaged audience at the Quality Management Session 3 on the 9th edition of the FACT-JACIE standards! #EBMT25

010

Reposted by Rémy Duléry

American Association for Cancer Research (AACR) @theaacr.bsky.social · 18/02/2025

AACR urges Congress to reaffirm its long history of steadfast and bipartisan support for medical research by ensuring that NIH has all of the resources needed to advance its lifesaving mission to prevent, diagnose, and treat cancer and other diseases: AACR.org/NIH

aacr.org

AACR Legislative Action Center

Directly contact your elected officials about the importance of cancer research, the need for continued funding and the latest lifesaving breakthroughs. In the United States, you can do so by sending ...

05833

Reposted by Rémy Duléry

Sen. Adam Schiff @schiff.senate.gov · 08/02/2025

Trump & Musk are making massive cuts to the National Institutes of Health. I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.

46747601212

Reposted by Rémy Duléry

Shernan Holtan, MD (she/her) @sghmd.bsky.social · 09/02/2025

Academic medicine colleagues, I worry we missed the boat on scientific communication. If we did a better job of explaining what we do and how we do it, half the country wouldn’t be so happy about defunding us right now.

043

Reposted by Rémy Duléry

Sylvain Lamure @sylvainlamure.bsky.social · 08/02/2025

Thank you Rémy for promoting this paper ! This confirmatory study reinforce the body of evidence to vaccine patients against COVID-19 BEFORE and AFTER anti-CD20 immunochemotherapy against Lymphoma

131

Rémy Duléry @remydulery.bsky.social · 07/02/2025

Happy to share this study! We prospectively evaluated CD4, CD8 T-cell and serological responses to the #COVID19 mRNA vaccine in a B-cell lymphoma patients treated with anti-CD20 therapy. Kudos to Caroline Besson & @sylvainlamure.bsky.social for leading this work. www.frontiersin.org/journals/imm...

frontiersin.org

Frontiers | Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine

131

Rémy Duléry @remydulery.bsky.social · 24/01/2025

Here is another remarkable study by the LYSA, published in @Hemasphere-journal.bsky.social! It evaluates the efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma with matched cohort analysis. Kudos to Amira Marouf for leading this collaborative work. onlinelibrary.wiley.com/doi/full/10....

onlinelibrary.wiley.com

Efficacy of anti‐PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA

Click on the article title to read more.

111

Rémy Duléry @remydulery.bsky.social · 22/01/2025

Happy to share our study on postoperative stage 0 Hodgkin lymphoma published in @hemasphere-journal.bsky.social Congrats to Audrey Couturier and Guillaume Manson for leading this work. Is surgery alone a curative option? Find some answers in our article! ⬇️ onlinelibrary.wiley.com/doi/10.1002/...

onlinelibrary.wiley.com

Postoperative stage 0 Hodgkin lymphoma. Is surgery alone a curative option?

Click on the article title to read more.

031

Reposted by Rémy Duléry

Rémy Duléry @remydulery.bsky.social · 08/01/2025

Happy to share our work published in Nature Medicine! We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...

nature.com

T cell malignancies after CAR T cell therapy in the DESCAR-T registry - Nature Medicine

This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France between 2018 and 2024 shows th...

1165

Reposted by Rémy Duléry

Johanna Joyce @johannajoyce.bsky.social · 10/01/2025

Disappointing new study showing - once again - that women are leaving research careers at far higher levels than men If you're interested to read about strategies to reverse these types of curves, check out our recent #Cell perspective- link below ⤵️ #WomeninSTEM 👩‍🔬👩🏾‍🔬🧪 www.nature.com/articles/d41...

Among nearly 35,000 biological scientists who authored their first paper in 2000, women were more likely than men to have stopped publishing after 5, 10 or 20 years. The size of this gender gap varies between disciplines.

12294135

Reposted by Rémy Duléry

John De Vos @jdevos.bsky.social · 10/01/2025

Analysis of 3,066 patients who received #CARTCell therapy in France, since 2018. Only one patient (0.03%) developed a T-cell malignancy after CAR T infusion, with insertion of the CAR into a tumor suppressor gene. Conclusion: there might be a very low risk of T-cell malignancy after CAR T therapy.

152

Reposted by Rémy Duléry

Jon Douglas @atranscendedman.bsky.social · 08/01/2025

A French study of 3,066 patients who received CAR T-cell therapy found an extremely low incidence (0.03%) of T-cell malignancies post-treatment. Only one case was observed over six years, suggesting the treatment is largely safe in this regard. www.nature.com/articles/s41...

nature.com

T cell malignancies after CAR T cell therapy in the DESCAR-T registry - Nature Medicine

0145

Reposted by Rémy Duléry

Krish Patel, MD @krishpatelmd.bsky.social · 08/01/2025

Amazing and very important work for the field. 👏🏽👏🏽👏🏽

041

Rémy Duléry @remydulery.bsky.social · 08/01/2025

nature.com

T cell malignancies after CAR T cell therapy in the DESCAR-T registry - Nature Medicine

1165

Rémy Duléry @remydulery.bsky.social · 06/01/2025

Here is a video where I discuss the management and treatment options for patients with DLBCL who are not eligible for CAR T-cell therapy. #VuMedi #CAR_T #lymsm #Medsky www.vumedi.com/video/treati...

vumedi.com

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

A video from Remy Dulery, posted on Dec 18, 2024.

082

Reposted by Rémy Duléry

Ajay Major, MD, MBA @majorajay.bsky.social · 07/12/2024

Post-CAR MCL DESCAR-T registry: - 1-yr OS after brexu-cel failure 30% - post-CAR outcomes better with RT (ORR 50%) and BsAb (ORR 43%) - 1-yr OS 57% w/ BsAb - most deaths due to MCL, some infections 2nd #ASH24 dataset showing better outcomes w/ BsAb in MCL post-CAR setting. #lymsm

041

Reposted by Rémy Duléry

Ajay Major, MD, MBA @majorajay.bsky.social · 08/12/2024

CAR-T outcomes based on nodal +/- extranodal @gloria_iacoboni #ASH24 - post-CAR OS worse if nodal+EN - ORR worse with increasing # of EN sites - sites w/ worse outcomes: bone, liver, GI, renal/adrenal, pancreas - network analysis reveals connected sites #lymsm #tcellrx

092

Reposted by Rémy Duléry

Ajay Major, MD, MBA @majorajay.bsky.social · 08/12/2024

#ASH24 plenary: ketogenic diet & CAR-T efficacy - ketogenic diet➡️cytokine release & CAR expansion in mouse xenograft via beta-hydroxybutyrate - in pts, BHB correlates w/ CAR expansion and giving BHB to 3 pts enhanced T-cell oxphos Fascinating! BHB + CAR-T trial is open. #tcellrx

0102

Reposted by Rémy Duléry

Ajay Major, MD, MBA @majorajay.bsky.social · 09/12/2024

Brexu-cel ZUMA-2 in BTKi naive pts #ASH24 - 86 pts, mFU 16 mos - 1-yr PFS 75%, OS 90%; 1-yr DOR 80% for responders - 6% G3+ CRS, 21% G3+ ICANS! - COD: 7 deaths d/t AEs My preference is for liso-cel given better toxicity profile (or cytoreduce with BTKi). #lymsm #tcellrx

042

Reposted by Rémy Duléry

Miguel Perales MD @drmiguelperales.bsky.social · 07/12/2024

Excellent data with PEMBRO-GVD in relapsed #Hodgkin lymphoma in study by @mskcancercenter.bsky.social Alison Moskowitz - she will present additional data tomorrow #ash24 #lymsm

0185

Rémy Duléry @remydulery.bsky.social · 02/12/2024

A highly anticipated new CAR-T cell therapy for B-cell ALL and a great news for the patients! Congratulations to Claire Roddie and the team behind the FELIX trial, leading to the FDA approval of Obecabtagene autoleucel. Read the full article here: www.nejm.org/doi/full/10....

093

Reposted by Rémy Duléry

Miguel Perales MD @drmiguelperales.bsky.social · 22/11/2024

If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW

14226

Reposted by Rémy Duléry

Nihar Desai MD, DM @nihardesai7.bsky.social · 21/11/2024

🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼 doi.org/10.1182/bloo... #MedSky #HemeSky

43611